Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2064

miRNAs as therapeutic modulators to treat blood cancers

Inventors: Francisco Navarro, Judy Lieberman

Invention Types: Therapeutics

Research Areas: Oncology/Hematology

Keywords:

For More Information Contact:  Dietz, Ryan

 

Invention Description:

MicroRNAs (miRNAs) are small non-coding RNAs that influence gene expression in order to regulate cell processes including differentiation and survival. Altered activity of miRNAs is implicated in leukemogenesis and the pathogenesis of cancer in general.


miR-34a loss is observed in cases of glioma, neuroblastoma, pancreatic cancer, and chronic myelogenous leukemia. The lab of Judy Lieberman at Boston Children’s has demonstrated that miR-34a is a key regulator of hematopoiesis that acts as a tumor suppressor to help prevent blood cancers. By studying K562 cells, a progenitor blood cell line with the potential to differentiate into either megakaryocytes or red blood cells, the researchers found that miR-34a facilitates differentiation to a megakaryocyte state. miR-34a does this by decreasing expression of the transcription factor MYB, a key regulator of multiple decision forks in hematopoiesis. Also, the researchers found that overexpression of miR-34a induces cell cycle arrest and blocks proliferation by repressing CDK4 and CDK6. This supports the role of miR-34a as a tumor suppressor and suggests further exploration into the use of RNAi-based drugs to mimic tumor suppressor miRNAs or antagonize the function of oncogenic miRNAs in blood cancers.

Applications:

• Therapeutic activators of miR-34a expression or function as a treatment for cancers with low miR34-a levels, including chronic myelogenous leukemia, glioma, neuroblastoma and pancreatic cancer

• Mimics of miR34-a as a treatment for the above cancers

Competitive Advantages:

• miRNA34-a is a tumor suppressor known to have decreased expression in specific cancer types

• Targets of miR-34a are known and include MYB, CDK4 and CDK6

Business Opportunity:

Collaboration or license opportunities available

Key Publications: Navarro F, Gutman D, Meire E, Cáceres M, Rigoutsos I, Bentwich Z, Lieberman J. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood. 2009 Sep 3;114(10):2181-92.

Navarro F, Lieberman J. miR-34 and p53: New insights into a complex functional relationship. PLoS ONE 10(7)

Lal A, Thomas MP, Altschuler G, et al. Capture of microRNA-bound mRNA identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011. 7(11).


US Patent #8,389,486

IPStatus: Patented